COPD-related HCRU for incident users over 12 months and at 0–3 months prior to index in incident users
| Total incident users | Non-triple users | IMT users | ||||||||||
| Overall n=13 451 | BDP/FOR n=6122 | BUD/FOR n=2703 | Other ICS/LABA* n=6122 | Overall n=7448 | BDP/FOR n=3601 | BUD/FOR n=1432 | Other ICS/LABA* n=2515 | Overall n=5162 | BDP/FOR n=2427 | BUD/FOR n=1056 | Other ICS/LABA* n=1679 | |
| 12 months prior to index | ||||||||||||
| GP consultations, n (%)† | 9850 (73.2) | 4493 (73.4) | 1961 (72.5) | 3396 (73.4) | 5081 (68.2) | 2496 (69.3) | 959 (67.0) | 1626 (67.3) | 3196 (61.9) | 1544 (63.6) | 626 (59.3) | 1026 (61.1) |
| Events, mean (SD)‡ | 2.4 (1.8) | 2.4 (1.8) | 2.4 (1.7) | 2.4 (1.7) | 2.2 (1.6) | 2.2 (1.7) | 2.2 (1.5) | 2.1 (1.6) | 1.9 (1.4) | 1.9 (1.4) | 2.0 (1.5) | 1.8 (1.2) |
| Outpatient visits, n (%)† | 2180 (16.2) | 1039 (17.0) | 426 (15.8) | 715 (15.5) | 1074 (14.4) | 560 (15.6) | 201 (14.0) | 313 (13.0) | 747 (14.5) | 383 (15.8) | 149 (14.1) | 215 (12.8) |
| Events, mean (SD)‡ | 2.4 (2.4) | 2.4 (2.5) | 2.2 (2.0) | 2.5 (2.5) | 2.2 (2.1) | 2.2 (2.1) | 2.0 (1.4) | 2.3 (2.5) | 2.1 (1.9) | 2.1 (2.0) | 2.1 (1.4) | 2.1 (2.0) |
| Inpatient stays, n (%)† | 3146 (23.4) | 1395 (22.8) | 613 (22.7) | 1138 (24.6) | 1444 (19.4) | 709 (19.7) | 258 (18.0) | 477 (19.8) | 869 (16.8) | 410 (16.9) | 172 (16.3) | 287 (17.1) |
| Events, mean (SD)‡ | 1.8 (2.0) | 1.8 (2.1) | 1.8 (2.5) | 1.8 (1.6) | 1.8 (1.8) | 1.8 (2.0) | 1.6 (1.4) | 1.8 (1.8) | 1.5 (1.3) | 1.5 (1.4) | 1.3 (0.8) | 1.6 (1.6) |
| A&E visits, n (%)† | 334 (2.5) | 150 (2.5) | 52 (1.9) | 132 (2.9) | 147 (2.0) | 85 (2.4) | 18 (1.3) | 44 (1.8) | 88 (1.7) | 41 (1.7) | 12 (1.1) | 35 (2.1) |
| Events, mean (SD)‡ | 1.2 (0.6) | 1.3 (0.6) | 1.2 (0.4) | 1.3 (0.7) | 1.2 (0.5) | 1.2 (0.6) | 1.0 (0) | 1.2 (0.5) | 1.1 (0.3) | 1.1 (0.3) | 1.0 (0) | 1.1 (0.4) |
| 0–3 months prior to index | ||||||||||||
| GP consultations, n (%)† | 5769 (42.9) | 2635 (43.0) | 1169 (43.3) | 1965 (42.5) | 2847 (38.2) | 1409 (39.1) | 538 (37.6) | 900 (37.3) | 1897 (36.8) | 911 (37.5) | 377 (35.7) | 609 (36.3) |
| Events, mean (SD)‡ | 1.5 (0.8) | 1.5 (0.8) | 1.4 (0.8) | 1.4 (0.7) | 1.3 (0.7) | 1.4 (0.7) | 1.4 (0.7) | 1.3 (0.6) | 1.3 (0.6) | 1.3 (0.6) | 1.4 (0.7) | 1.3 (0.6) |
| Outpatient visits, n (%)† | 1473 (11.0) | 725 (11.8) | 295 (10.9) | 453 (9.8) | 710 (9.5) | 382 (10.6) | 143 (10.0) | 185 (7.7) | 534 (10.3) | 270 (11.1) | 115 (10.9) | 149 (8.9) |
| Events, mean (SD)‡ | 1.6 (1.4) | 1.6 (1.4) | 1.5 (0.8) | 1.7 (1.7) | 1.5 (1.4) | 1.5 (1.4) | 1.4 (0.8) | 1.6 (1.7) | 1.5 (1.1) | 1.5 (1.2) | 1.4 (0.7) | 1.5 (1.0) |
| Inpatient stays, n (%)† | 1738 (12.9) | 769 (12.6) | 334 (12.4) | 635 (13.7) | 768 (10.3) | 388 (10.8) | 130 (9.1) | 250 (10.4) | 519 (10.1) | 238 (9.8) | 103 (9.8) | 178 (10.6) |
| Events, mean (SD)‡ | 1.4 (1.2) | 1.4 (1.5) | 1.3 (0.9) | 1.3 (0.8) | 1.3 (0.7) | 1.3 (0.8) | 1.3 (0.7) | 1.3 (0.7) | 1.2 (0.6) | 1.2 (0.6) | 1.1 (0.4) | 1.2 (0.7) |
| A&E visits, n (%)† | 190 (1.4) | 89 (1.5) | 28 (1.0) | 73 (1.6) | 84 (1.1) | 52 (1.4) | 9 (0.6) | 23 (1.0) | 56 (1.1) | 25 (1.0) | 7 (0.7) | 24 (1.4) |
| Events, mean (SD)‡ | 1.2 (0.5) | 1.2 (0.5) | 1.2 (0.5) | 1.2 (0.6) | 1.1 (0.4) | 1.2 (0.4) | 1 (0) | 1.1 (0.3) | 1.1 (0.3) | 1.1 (0.3) | 1 (0) | 1.1 (0.3) |
*Included fluticasone propionate/salmeterol, fluticasone propionate/formoterol fumarate and fluticasone furoate/vilanterol.
†Defined as patients who had at least one unit of use for respective healthcare service.
‡Calculated only for patients with ≥1 use during the time period.
A&E, accident and emergency; BDP, beclomethasone dipropionate; BUD, budesonide; COPD, chronic obstructive pulmonary disease; FOR, formoterol; GP, general practice; HCRU, healthcare resource utilisation; ICS, inhaled corticosteroids; IMT, initial maintenance therapy; LABA, long-acting β2-agonist.